




MEDICINAL PRODUCTS 2020

Foamix Pharmaceuticals Ltd.
Rank 44 of 52





RealRate

MEDICINAL PRODUCTS 2020

Foamix Pharmaceuticals Ltd.
Rank 44 of 52



The relative strengths and weaknesses of Foamix Pharmaceuticals Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Foamix Pharmaceuticals Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Foamix Pharmaceuticals Ltd. is the variable Net Income, reducing the Economic Capital Ratio by 85% points.

The company's Economic Capital Ratio, given in the ranking table, is -111%, being 107% points below the market average of -4.3%.

Input Variable	Value in 1000 USD
Assets, Current	76,414
Assets, Non-Current	4,745
General and Administrative Expense	45,114
Goodwill	0
Liabilities, Current	29,326
Liabilities, Non-Current	34,258
Other Assets	-2,885
Other Compr. Net Income	0
Other Expenses	977
Other Liabilities	0
Other Net Income	1,672
Other Revenues	443
Property, Plant and Equipment, Net	2,885
Research and Development	51,202

Output Variable	Value in 1000 USD
Liabilities	63,584
Assets	81,159
Expenses	97,293
Revenues	443
Stockholders Equity	17,575
Net Income	-95,178
Comprehensive Net Income	-95,178
Economic Capital Ratio	-111%